Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 621

1.

Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema.

Kang YK, Park HS, Park DH, Shin JP.

Sci Rep. 2020 Jan 17;10(1):528. doi: 10.1038/s41598-020-57509-6.

PMID:
31953511
2.

Development of a Physics-Based Molecular Force Field for Biomolecule Simulations.

Hwang S, Lee CJ, Lee S, Ma S, Kang YM, Cho KH, Kim SY, Kwon OY, Yoon CN, Kang YK, Yoon JH, Nam KY, Kim SG, In Y, Chai HH, Acree WE, Grant JA, Gibson KD, Jhon MS, Scheraga HA, No KT.

J Phys Chem B. 2020 Jan 15. doi: 10.1021/acs.jpcb.9b10339. [Epub ahead of print]

PMID:
31939671
3.

Distance Dependence of Electronic Coupling in Rigid, Cofacially Compressed, π-Stacked Organic Mixed-Valence Systems.

Jung HW, Yoon SE, Carroll PJ, Gau MR, Therien MJ, Kang YK.

J Phys Chem B. 2020 Jan 13. doi: 10.1021/acs.jpcb.9b09578. [Epub ahead of print]

PMID:
31927963
4.

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.

Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N.

Gastric Cancer. 2019 Dec 20. doi: 10.1007/s10120-019-01034-7. [Epub ahead of print]

PMID:
31863227
5.

A skin-like two-dimensionally pixelized full-color quantum dot photodetector.

Kim J, Kwon SM, Kang YK, Kim YH, Lee MJ, Han K, Facchetti A, Kim MG, Park SK.

Sci Adv. 2019 Nov 22;5(11):eaax8801. doi: 10.1126/sciadv.aax8801. eCollection 2019 Nov.

6.

Retroelement Insertion in a CRISPR/Cas9 Editing Site in the Early Embryo Intensifies Genetic Mosaicism.

Jeon J, Park JS, Min B, Chung SK, Kim MK, Kang YK.

Front Cell Dev Biol. 2019 Nov 8;7:273. doi: 10.3389/fcell.2019.00273. eCollection 2019.

7.

Standardized Pathology Report for Colorectal Cancer, 2nd Edition.

Kim BH, Kim JM, Kang GH, Chang HJ, Kang DW, Kim JH, Bae JM, Seo AN, Park HS, Kang YK, Lee KH, Cho MY, Do IG, Lee HS, Chang HK, Park DY, Kang HJ, Sohn JH, Chang MS, Jung ES, Jin SY, Yu E, Han HS, Kim YW; Gastrointestinal Pathology Study Group of the Korean Society of Pathologists.

J Pathol Transl Med. 2019 Nov 13. doi: 10.4132/jptm.2019.09.28. [Epub ahead of print]

8.

Orientational Dependence of Cofacial Porphyrin-Quinone Electronic Interactions within the Strong Coupling Regime.

Kang YK, Zhang P, Rubtsov IV, Zheng J, Bullard G, Beratan DN, Therien MJ.

J Phys Chem B. 2019 Dec 12;123(49):10456-10462. doi: 10.1021/acs.jpcb.9b07627. Epub 2019 Dec 2.

PMID:
31710233
9.

Angiographic features of drug-induced bilateral angle closure and transient myopia with Ciliochoroidal effusion.

Kang YK, Son BJ, Park DH, Shin JP.

BMC Ophthalmol. 2019 Nov 4;19(1):213. doi: 10.1186/s12886-019-1230-y.

10.

Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M.

J Hepatol. 2019 Dec;71(6):1278. doi: 10.1016/j.jhep.2019.09.013. Epub 2019 Oct 25. No abstract available.

PMID:
31668671
11.

Large-Scale Sonochemical Synthesis of Bi-Sn Eutectic Alloy Nanoparticles.

Kang YK, Kim J, Darko K, Park SK, Kim MG.

J Nanosci Nanotechnol. 2020 May 1;20(5):3201-3205. doi: 10.1166/jnn.2020.17394.

PMID:
31635665
12.

Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.

Chae H, Ryu MH, Ma J, Beck M, Kang YK.

Invest New Drugs. 2019 Oct 18. doi: 10.1007/s10637-019-00860-x. [Epub ahead of print]

PMID:
31628586
13.

Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.

Yoo C, Ryu YM, Kim SY, Kim J, Ock CY, Ryu MH, Kang YK.

Br J Cancer. 2019 Nov;121(10):819-826. doi: 10.1038/s41416-019-0596-1. Epub 2019 Oct 14.

PMID:
31607749
14.

Soft Windowing Application to Improve Analysis of High-throughput Phenotyping Data.

Haselimashhadi H, Mason JC, Munoz-Fuentes V, López-Gómez F, Babalola K, Acar EF, Kumar V, White J, Flenniken AM, King R, Straiton E, Seavitt JR, Gaspero A, Garza A, Christianson AE, Hsu CW, Reynolds CL, Lanza DG, Lorenzo I, Green JR, Gallegos JJ, Bohat R, Samaco RC, Veeraragavan S, Kim JK, Miller G, Fuchs H, Garrett L, Becker L, Kang YK, Clary D, Cho SY, Tamura M, Tanaka N, Soo KD, Bezginov A, About GB, Champy MF, Vasseur L, Leblanc S, Meziane H, Selloum M, Reilly PT, Spielmann N, Maier H, Gailus-Durner V, Sorg T, Hiroshi M, Yuichi O, Heaney JD, Dickinson ME, Wolfgang W, Tocchini-Valentini GP, Lloyd KCK, McKerlie C, Seong JK, Yann H, de Angelis MH, Brown SDM, Smedley D, Flicek P, Mallon AM, Parkinson H, Meehan TF.

Bioinformatics. 2019 Oct 8. pii: btz744. doi: 10.1093/bioinformatics/btz744. [Epub ahead of print]

PMID:
31591642
15.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.

PMID:
31575541
16.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP.

Cancer Discov. 2019 Dec;9(12):1686-1695. doi: 10.1158/2159-8290.CD-19-0367. Epub 2019 Oct 1.

PMID:
31575540
17.

Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy.

Seo S, Ryu MH, Ryoo BY, Park Y, Park YS, Na YS, Lee CW, Lee JK, Kang YK.

Chin J Cancer Res. 2019 Aug;31(4):620-631. doi: 10.21147/j.issn.1000-9604.2019.04.06.

18.

Demethylation and derepression of genomic retroelements in the skeletal muscles of aged mice.

Min B, Jeon K, Park JS, Kang YK.

Aging Cell. 2019 Dec;18(6):e13042. doi: 10.1111/acel.13042. Epub 2019 Sep 27.

19.

Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial.

Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F.

J Cachexia Sarcopenia Muscle. 2019 Aug 28. doi: 10.1002/jcsm.12484. [Epub ahead of print]

20.

Organocatalytic Asymmetric Addition of Aldehyde to Nitroolefin by H-d-Pro-Pro-Glu-NH2: A Mechanistic Study.

Maillard LT, Park HS, Kang YK.

ACS Omega. 2019 May 22;4(5):8862-8873. doi: 10.1021/acsomega.9b00465. eCollection 2019 May 31.

21.

Compartmental-modelling-based measurement of murine glomerular filtration rate using 18F-fluoride PET/CT.

Lee HS, Kang YK, Lee H, Han JH, Moon BS, Byun SS, Chae DW, Kang KW, Lee WW.

Sci Rep. 2019 Aug 2;9(1):11269. doi: 10.1038/s41598-019-47728-x.

22.

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.

Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y.

JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243.

23.

Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.

Kim H, An S, Lee K, Ahn S, Park DY, Kim JH, Kang DW, Kim MJ, Chang MS, Jung ES, Kim JM, Choi YJ, Jin SY, Chang HK, Cho MY, Kang YK, Kang M, Ahn S, Kim YW, Hong SM; Gastrointestinal Pathology Study Group of the Korean Society of Pathologists.

Cancer Res Treat. 2020 Jan;52(1):263-276. doi: 10.4143/crt.2019.192. Epub 2019 Jul 12.

24.

Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.

Cho H, Ryu MH, Lee Y, Park YS, Kim KH, Kim JH, Park Y, Lee SM, Kim CW, Kim BS, Yoo MW, Kang YK.

Oncologist. 2019 Dec;24(12):e1443-e1449. doi: 10.1634/theoncologist.2019-0009. Epub 2019 Jul 17.

25.

PREVALENCE AND TIME TRENDS OF MYOPIA IN CHILDREN AND ADOLESCENTS IN CHINA: A Systemic Review and Meta-Analysis.

Dong L, Kang YK, Li Y, Wei WB, Jonas JB.

Retina. 2019 Jun 21. doi: 10.1097/IAE.0000000000002590. [Epub ahead of print]

PMID:
31259808
26.

Systemic identification and analyses of genes potentially involved in chemosensory in the devastating tea pest Basilepta melanopus.

Zhou LY, Li W, Liu HY, Xiang F, Kang YK, Yin X, Huang AP, Wang YJ.

Comp Biochem Physiol Part D Genomics Proteomics. 2019 Sep;31:100586. doi: 10.1016/j.cbd.2019.04.002. Epub 2019 May 28.

PMID:
31195215
27.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PM, Shah MA, Shen L, Kang YK, Alsina M, Girish S, Garg A.

Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.

28.

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M.

J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7. Erratum in: J Hepatol. 2019 Dec;71(6):1278.

30.

Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.

Kang YK, Choi JY, Paeng JC, Kim YI, Kwon HW, Cheon GJ, Suh KS, Kwon CHD, Lee DS, Kang KW.

Eur Radiol. 2019 Nov;29(11):6009-6017. doi: 10.1007/s00330-019-06239-z. Epub 2019 May 21.

PMID:
31115626
31.

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.

Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, Chen JS, Muro K, Ki Kang W, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N.

Gastric Cancer. 2020 Jan;23(1):143-153. doi: 10.1007/s10120-019-00970-8. Epub 2019 May 13.

32.

Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors - 8 cases: A case report.

Kim JH, Ryu MH, Park YS, Kim HJ, Park H, Kang YK.

World J Gastroenterol. 2019 Apr 28;25(16):2010-2018. doi: 10.3748/wjg.v25.i16.2010.

33.

Ocular size and shape in lens-induced Myopization in young Guinea pigs.

Dong L, Shi XH, Kang YK, Wei WB, Wang YX, Jonas JB.

BMC Ophthalmol. 2019 May 3;19(1):102. doi: 10.1186/s12886-019-1109-y.

34.

Bruch's Membrane Thickness and Retinal Pigment Epithelium Cell Density in Experimental Axial Elongation.

Dong L, Shi XH, Kang YK, Wei WB, Wang YX, Xu XL, Gao F, Jonas JB.

Sci Rep. 2019 Apr 29;9(1):6621. doi: 10.1038/s41598-019-43212-8.

35.

Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.

Kim JJ, Ryu MH, Yoo C, Beck MY, Ma JE, Kang YK.

Oncologist. 2019 Nov;24(11):e1212-e1218. doi: 10.1634/theoncologist.2019-0033. Epub 2019 Apr 29.

36.

Perioperative FLOT: new standard for gastric cancer?

Kang YK, Cho H.

Lancet. 2019 May 11;393(10184):1914-1916. doi: 10.1016/S0140-6736(18)33189-1. Epub 2019 Apr 11. No abstract available.

PMID:
30982685
37.

Weakly supervised lesion localization for age-related macular degeneration detection using optical coherence tomography images.

Yang HL, Kim JJ, Kim JH, Kang YK, Park DH, Park HS, Kim HK, Kim MS.

PLoS One. 2019 Apr 5;14(4):e0215076. doi: 10.1371/journal.pone.0215076. eCollection 2019.

38.

Prospect of Thiazole-based γ-Peptide Foldamers in Enamine Catalysis: Exploration of the Nitro-Michael Addition.

Aguesseau-Kondrotas J, Simon M, Legrand B, Bantigniès JL, Kang YK, Dumitrescu D, Van der Lee A, Campagne JM, de Figueiredo RM, Maillard LT.

Chemistry. 2019 May 28;25(30):7396-7401. doi: 10.1002/chem.201901221. Epub 2019 May 7.

PMID:
30946485
39.

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC.

Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.

40.

Amphiregulin and ocular axial length.

Dong L, Shi XH, Kang YK, Wei WB, Wang YX, Xu XL, Gao F, Yuan LH, Zhen J, Jiang WJ, Jonas JB.

Acta Ophthalmol. 2019 May;97(3):e460-e470. doi: 10.1111/aos.14080. Epub 2019 Mar 12.

PMID:
30860674
41.

A Case of Autosomal Dominant Osteopetrosis Type 2 with a CLCN7 Gene Mutation

Kang S, Kang YK, Lee JA, Kim DH, Lim JS.

J Clin Res Pediatr Endocrinol. 2019 Nov 22;11(4):439-443. doi: 10.4274/jcrpe.galenos.2019.2018.0229. Epub 2019 Feb 14.

42.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

43.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.

Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.

PMID:
30706247
44.

Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.

Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, Kim BS, Yoo MW, Yook JH, Kim BS, Kim KH, Kim CW, Kang YK.

Cancer Med. 2019 Mar;8(3):1034-1043. doi: 10.1002/cam4.1994. Epub 2019 Jan 28.

45.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
46.

Epidemiology of chronic airway disease: results from a cross-sectional survey in Beijing, China.

Zhang H, Dong L, Kang YK, Lu Y, Wei HH, Huang J, Wang X, Huang K.

J Thorac Dis. 2018 Nov;10(11):6168-6175. doi: 10.21037/jtd.2018.10.44.

47.

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.

Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA.

Eur J Cancer. 2019 Feb;108:17-24. doi: 10.1016/j.ejca.2018.11.017. Epub 2018 Dec 25.

PMID:
30592991
48.

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).

Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK.

Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540.

49.

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N.

Gastric Cancer. 2019 Mar;22(2):344-354. doi: 10.1007/s10120-018-0899-6. Epub 2018 Dec 1.

50.

Correction to "Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance".

Kang YK, Kwon K, Ryu JS, Lee HN, Park C, Chung HJ.

Bioconjug Chem. 2018 Nov 21;29(11):3936. doi: 10.1021/acs.bioconjchem.8b00771. Epub 2018 Nov 12. No abstract available.

PMID:
30418758

Supplemental Content

Support Center